Expert Interview
A Third View: Discussing the Losmapimod data for Facioscapulohumeral muscular dystrophy (FSHD) from Fulcrum Therapeutics
Ticker(s): FULCInstitution: Texas Children's Hospital / Baylor College of Medicine
- Assistant Professor of Pediatric Neurology at Baylor College of Medicine.
- Manages 36 patients with SMA and 85 patients with DMD per year.
- PI on several clinical trials including the pamrevlumab study; Clinical and research interest in muscular dystrophy with focus on Duchenne Muscular Dystrophy.
How many FSHD patients do you treat?
Added By: wilson_adminWhat are your opinions of the phase 2 data?
Added By: wilson_adminWhat do you think about the phase 3 trial design?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
